Digital Health and Big Data Analytics: Implications of Real-World Evidence for Clinicians and Policymakers

Int J Environ Res Public Health. 2022 Jul 8;19(14):8364. doi: 10.3390/ijerph19148364.

Abstract

Real world data (RWD) and real-world evidence (RWE) plays an increasingly important role in clinical research since scientific knowledge is obtained during routine clinical large-scale practice and not experimentally as occurs in the highly controlled traditional clinical trials. Particularly, the electronic health records (EHRs) are a relevant source of data. Nevertheless, there are also significant challenges in the correct use and interpretation of EHRs data, such as bias, heterogeneity of the population, and missing or non-standardized data formats. Despite the RWD and RWE recognized difficulties, these are easily outweighed by the benefits of ensuring the efficacy, safety, and cost-effectiveness in complement to the gold standards of the randomized controlled trial (RCT), namely by providing a complete picture regarding factors and variables that can guide robust clinical decisions. Their relevance can be even further evident as healthcare units develop more accurate EHRs always in the respect for the privacy of patient data. This editorial is an overview of the RWD and RWE major aspects of the state of the art and supports the Special Issue on "Digital Health and Big Data Analytics: Implications of Real-World Evidence for Clinicians and Policymakers" aimed to explore all the potential and the utility of RWD and RWE in offering insights on diseases in a broad spectrum.

Keywords: big data; digital health; healthcare; real-world data; real-world evidence.

Publication types

  • Editorial

MeSH terms

  • Bias
  • Cost-Benefit Analysis
  • Data Science*
  • Delivery of Health Care
  • Electronic Health Records*
  • Humans
  • Randomized Controlled Trials as Topic

Grants and funding

The author has no relevant affiliation or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.